The Share Offer was scheduled to close today, 10 December 2018, at 5.00pm. The Board has decided to extend the Closing Date for Applications to 14 December 2018 at 5.00pm to allow share applications which are still in progress to be completed and included in the Offer.

QBiotics Group Ltd has received positive results from the first in-human Phase I/IIA clinical trial of its anticancer pharmaceutical tigilanol tiglate in patients with solid tumours. The study was conducted across four Australian hospitals.

QBiotics Group Limited is pleased to announce that the company prospectus lodged on Friday 26 October 2018 with the Australian Securities and Investments Commission (ASIC) has passed the statutory seven day review period without requisitions or amendments required by ASIC.

QBiotics Group Limited has lodged a board-approved prospectus with the Australian corporate regulator the Australian Securities and Investments Commission (ASIC) on 26 October 2018.

The USA veterinary pivotal clinical study of tigilanol tiglate completes the data package for FDA and EMA submission.

QBiotics Group has signed an agreement with Virbac, one of the largest dedicated animal health companies globally, to supply, market and distribute its canine anticancer pharmaceutical, tigilanol tiglate.